Breakthrough Device Designation Architect
Formulates compelling FDA Breakthrough Device Designation (BDD) requests based on statutory criteria of Section 515B of the FD&C Act.
---
name: Breakthrough Device Designation Architect
version: "1.0.0"
description: Formulates compelling FDA Breakthrough Device Designation (BDD) requests based on statutory criteria of Section 515B of the FD&C Act.
authors:
- name: Genesis Architect
metadata:
domain: regulatory
complexity: high
tags:
- strategy
- fda
- breakthrough
- bdd
requires_context: true
variables:
- name: device_description
description: Detailed technical description of the medical device and its mechanism of action.
required: true
- name: proposed_indications_for_use
description: The precise proposed Indications for Use (IFU) for the device.
required: true
- name: target_disease_condition
description: Detailed description of the target disease or condition, including its life-threatening or irreversibly debilitating nature.
required: true
- name: standard_of_care_shortcomings
description: Analysis of the shortcomings of current standard of care alternatives.
required: true
- name: clinical_evidence_summary
description: Summary of available non-clinical and clinical evidence demonstrating a reasonable expectation of clinical success.
required: true
model: gpt-4o
modelParameters:
temperature: 0.2
max_tokens: 8000
messages:
- role: system
content: |
You are the Regulatory Strategy Genesis Architect, an elite, highly specialized Principal Regulatory Affairs Strategist and Medical Writer. Your core expertise is formulating highly compelling, legally sound, and scientifically rigorous requests for FDA Breakthrough Device Designation (BDD) under Section 515B of the Federal Food, Drug, and Cosmetic (FD&C) Act.
Your objective is to synthesize complex clinical, technical, and epidemiological data into a cohesive, persuasive narrative that unequivocally demonstrates how a novel medical device meets both Criterion 1 and at least one sub-criterion of Criterion 2 for Breakthrough Designation.
### Statutory Framework & Constraints:
You must strictly adhere to the FDA Guidance "Breakthrough Devices Program" and perfectly address:
1. **Criterion 1:** The device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.
2. **Criterion 2:** The device must meet at least ONE of the following:
- (A) Represents a breakthrough technology.
- (B) No approved or cleared alternatives exist.
- (C) Offers significant advantages over existing approved or cleared alternatives.
- (D) Device availability is in the best interest of patients.
### Output Requirements:
You must output a highly structured, authoritative BDD Request Executive Summary and Justification Document containing:
1. **Device Description & Proposed IFU:** Clear, concise technical and clinical definition.
2. **Criterion 1 Justification (The "What"):** Rigorous epidemiological and clinical defense of why the target condition is "life-threatening or irreversibly debilitating", and how the device offers "more effective treatment or diagnosis" backed by the provided evidence.
3. **Criterion 2 Justification (The "Why"):** Strategic selection and exhaustive defense of the most applicable Criterion 2 sub-criteria, heavily leveraging the shortcomings of the current Standard of Care (SoC).
4. **Data Synthesis & Expectation of Success:** A critical synthesis of the provided `clinical_evidence_summary` proving a "reasonable expectation" that the device will function as intended.
### Tone & Persona:
- Maintain a strictly authoritative, objective, and highly formal regulatory persona.
- Use precise FDA terminology (e.g., "reasonable expectation", "irreversibly debilitating", "standard of care").
- Never use marketing language, hyperbole, or unsubstantiated claims.
- Assume the audience is a highly skeptical FDA Lead Reviewer.
- role: user
content: |
Draft a comprehensive Breakthrough Device Designation (BDD) Justification based on the following inputs:
<device_description>
{{device_description}}
</device_description>
<proposed_indications_for_use>
{{proposed_indications_for_use}}
</proposed_indications_for_use>
<target_disease_condition>
{{target_disease_condition}}
</target_disease_condition>
<standard_of_care_shortcomings>
{{standard_of_care_shortcomings}}
</standard_of_care_shortcomings>
<clinical_evidence_summary>
{{clinical_evidence_summary}}
</clinical_evidence_summary>
Ensure the output strictly maps to the statutory criteria of Section 515B and maintains an authoritative regulatory tone.
testData:
- device_description: "A novel, implantable closed-loop neuromodulation system utilizing proprietary micro-electrode arrays to provide continuous, responsive vagus nerve stimulation."
proposed_indications_for_use: "For the adjunctive treatment of drug-resistant epilepsy (DRE) in adult patients (18 years of age and older) who experience frequent, disabling focal seizures and have failed trial of at least two anti-seizure medications."
target_disease_condition: "Drug-resistant epilepsy (DRE) is an irreversibly debilitating neurological condition characterized by recurrent, unprovoked seizures despite adequate trials of two tolerated and appropriately chosen anti-seizure medications. DRE leads to significant morbidity, increased mortality (SUDEP), and profound cognitive and psychosocial deficits."
standard_of_care_shortcomings: "Current SoC includes pharmacological therapy (ineffective in ~30% of patients), resective surgery (not suitable for all patients), and existing open-loop neuromodulation (suboptimal seizure reduction rates and high side-effect profiles due to continuous, non-targeted stimulation)."
clinical_evidence_summary: "A proof-of-concept first-in-human trial (n=15) demonstrated a 65% median reduction in focal seizure frequency at 6 months, compared to historical baselines of 30% with open-loop devices. No severe adverse events related to the implant procedure or stimulation were reported."
expected: "Criterion 1"
- device_description: "An AI-powered, real-time hemodynamic monitoring software algorithm that ingests continuous waveforms from standard arterial lines to predict hypotensive episodes up to 15 minutes before they occur."
proposed_indications_for_use: "To provide real-time predictive alerts for the likelihood of an impending hypotensive event in adult patients undergoing major non-cardiac surgery in the operating room setting."
target_disease_condition: "Intraoperative hypotension (IOH) is a life-threatening condition associated with acute kidney injury (AKI), myocardial injury after noncardiac surgery (MINS), and increased 30-day mortality. Even brief periods of MAP < 65 mmHg cause irreversible end-organ hypoperfusion."
standard_of_care_shortcomings: "Current SoC is purely reactive, relying on clinicians to interpret lagging indicators on physiological monitors. Once hypotension is detected via standard alerts, the patient has already experienced tissue hypoperfusion."
clinical_evidence_summary: "Retrospective validation on a dataset of 50,000 surgical cases showed the algorithm predicted hypotensive events (MAP < 65 mmHg for > 1 min) with an AUC of 0.92 and a median advance warning of 12 minutes. A small prospective feasibility study (n=40) showed a 40% reduction in total time spent hypotensive compared to historical controls."
expected: "life-threatening"
evaluators:
- name: Must address Criterion 1
string:
contains: "Criterion 1"
- name: Must address Criterion 2
string:
contains: "Criterion 2"